Evolus, INC 8-K filings

Evolus, Inc. announced robust second quarter 2026 financial results, including a 21% increase in net revenue and a third consecutive quarter of positive Adjusted EBITDA, leading to an improved full-year financial outlook.

Evolus, Inc. has expanded its strategic partnership with Symatese, securing exclusive rights to commercialize the Estyme injectable HA gel collection in Canada, Australia, and New Zealand.

Evolus, Inc. has entered into an exclusive agreement with IBSA to develop and commercialize Profhilo, a leading injectable for skin quality, in the United States.

Evolus, Inc. stockholders elected two Class II directors, ratified its auditor, and approved executive compensation at the 2026 Annual Meeting.

Evolus, Inc. announced its first quarter 2026 financial results, achieving its second consecutive quarter of positive Adjusted EBITDA and reaffirming its full-year outlook.

Evolus, Inc. announced the reclassification of Vikram Malik from a Class III to a Class II director to restore balance to its classified board structure.

Evolus, Inc. announced preliminary unaudited net revenue for Q4 and full-year 2025, projecting continued double-digit growth and reaffirming 2026 profitability.

Evolus reported strong third-quarter 2025 financial results with total net revenue up 13% year-over-year, driven by Jeuveau and the successful launch of Evolysse, positioning the company for Q4 profitability.

Evolus, Inc. announced the appointment of Tatjana Mitchell, a seasoned finance executive from Experian and Zulily, as its new Chief Financial Officer, effective September 8, 2025.

Evolus, Inc. reported a 4% increase in Q2 2025 global net revenue to $69.4 million, driven by the successful Evolysse launch, but reset its full-year 2025 revenue guidance lower due to softened U.S. toxin demand.

Evolus, Inc. held its Annual Meeting of Stockholders on June 5, 2025, where shareholders approved all key proposals, including the election of Class I Directors, ratification of the independent auditor, and advisory approval of executive compensation, alongside a planned board transition.

Evolus, Inc. announced that Chief Financial Officer Sandra Beaver will voluntarily resign effective June 13, 2025, to pursue another opportunity, with the company emphasizing her departure is not due to disagreements and highlighting recent record revenues and strategic positioning for profitability.

Evolus announces a 15.5% increase in global net revenue for Q1 2025, reaching $68.5 million, and reaffirms its full-year revenue guidance of $345 million to $355 million.

Evolus refinanced its existing credit facility with a new $250 million agreement, lowering interest rates and increasing financial flexibility.

Evolus announces record global net revenue of $79.0 million for Q4 2024 and $266.3 million for full year 2024, representing 30% and 32% growth respectively, and reaffirms its 2025 revenue guidance.

Evolus reports record preliminary unaudited net revenue for 2024, exceeding guidance and projecting continued growth and profitability in 2025 with the upcoming launch of new products.

Evolus announced a 22% increase in third-quarter revenue, reaching $61.1 million, and secured European approval for its Estyme injectable hyaluronic acid gels.

Evolus reports its first profitable quarter with a 36% revenue increase year-over-year and raises its full-year revenue guidance to $260-$270 million.

Evolus, Inc. has appointed Albert G. White III to its Board of Directors, effective July 1, 2024, as part of a planned board refreshment.

Evolus, Inc. held its annual meeting where stockholders approved the 2024 Employee Stock Purchase Plan and elected three Class III directors.

Evolus announced a 42% increase in net revenue for Q1 2024 compared to Q1 2023, alongside progress towards profitability and expansion of their product portfolio.

Evolus Inc. disclosed that two board members, Robert Hayman and Simone Blank, will be stepping down as part of the company's board refreshment strategy.

Evolus Inc. has successfully completed a public offering of 3,554,000 shares of common stock, raising approximately $46.9 million in net proceeds.

Evolus announced record fourth quarter and full year 2023 financial results, highlighted by a 40% increase in Q4 revenue and reaffirmed its 2024 revenue guidance, while also projecting profitability by the fourth quarter of 2024.

Evolus reports preliminary unaudited full-year 2023 revenue of approximately $202 million, exceeding guidance and setting a strong foundation for 2024 growth.